Picture of Genetic Analysis As logo

GEAN Genetic Analysis As Cashflow Statement

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Annual cashflow statement for Genetic Analysis As, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSPRESS
Standards:
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-29-28.3-23.8-14.8-11.4
Depreciation
Non-Cash Items-3.152.73-0.892.469.51
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-0.0171.261.9-1.43-0.871
Change in Accounts Receivable
Change in Inventories
Change in Accounts Payable
Other Operating Cash Flow
Cash from Operating Activities-27.6-19.5-17.2-8.52.4
Capital Expenditures-1.95-0.227-0.643-1.95-5.54
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items0.018-0.5-0.1
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-1.94-0.227-1.14-2.05-5.54
Financing Cash Flow Items-0.289-1.32
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities52.2-1.89.347.6313.8
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash22.6-21.5-9.03-2.9210.7